skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes

Review

(1562) Views  (581) Full article downloads

Authors: Derosa G, Maffioli P

Published Date June 2011 Volume 2011:4 Pages 263 - 271
DOI: http://dx.doi.org/10.2147/DMSO.S16361

Giuseppe Derosa, Pamela Maffioli
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Introduction: Targeting glycated hemoglobin (HbA1c) levels below 7.0% is considered a primary goal of diabetes care, given its importance in obtaining a sustained reduction in microvascular, and possibly macrovascular complications.
Aim: The aim of this review was to evaluate the clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.
Evidence review: The combination of saxagliptin/metformin was well tolerated and produced sustained glycemic control for up to 76 weeks, with greater improvements in glycemic parameters compared with either drug alone. The saxagliptin/metformin combination also proved its non-inferiority compared with either sulfonylurea/metformin or sitagliptin/metformin combinations.
Place in therapy: Clinical practice recommends lifestyle interventions together with starting metformin at the time that the type 2 diabetes mellitus is diagnosed. Once metformin fails to maintain glycemic control, the addition of DPP-4 inhibitors should be the logical choice because of their effects on HbA1c compared to the addition of a sulfonylurea or glitazone, and because of their positive effects on beta cell function and their neutral effects on body weight. Furthermore, DPP-4 inhibitors prevent the risk of hypoglycemia posed by sulfonylureas.

Keywords: DPP-4 inhibitors, saxagliptin, glycemic control, insulin sensitivity, HOMA index




 

Other articles by Professor Giuseppe Derosa



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
CTLA-4 blockade: therapeutic potential in cancer treatments
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication
Profile of ipilimumab and its role in the treatment of metastatic melanoma
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma
Targeted agents for the treatment of metastatic melanoma
Obesity: considerations about etiology, metabolism, and the use of experimental models
Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan
Clinical features and treatment of maturity onset diabetes of the young (MODY)
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio